A New Treatment for Pyruvate Dehydrogenase Deficiency
| Reference number | |
| Coordinator | Pretzel Therapeutics Sweden AB |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | November 2024 - March 2026 |
| Status | Completed |
| Venture | Utlysning Infrastruktur for the development of accurate drug treatment |
| Call | Use infrastructures to develop precision medicine |
Important results from the project
Although the project did not produce all of the planned results laid out in our original application, it has concluded at a satisfactory point with meaningful scientific progress and high quality data. It also strengthened the links between Pretzel Therapeutics and nearby collaborators.
Expected long term effects
The project has enabled fundamental research that may support the development of therapies for rare diseases with significant unmet medical need. It has strengthened internal technical expertise, which will impact the quality and efficiency of future drug development efforts.
Approach and implementation
Pretzel Therapeutics collaborated on this project with OligoNova due to their expertise in siRNA design and testing. Regular meetings and in-person site visits were held between the parties to guide key decisions and advance the project.